Survival Rate and Prognosis for Osteosarcoma
Osteosarcoma is a rare but aggressive bone cancer that most often develops during the adolescent growth years. Understanding the osteosarcoma survival rate, how it differs by extent of disease and age, and the factors that shape an individual’s outlook can help patients and families know what to expect.
Key Takeaways
- National Cancer Institute registry figures put 5-year survival odds at about 72% for patients under age 15 at diagnosis and close to 71% for those diagnosed at ages 15 through 19 — a large improvement since the 1970s, though gains have leveled off since the 1980s.
- According to the National Cancer Institute, whether the cancer has already spread at diagnosis is the single biggest factor in prognosis: about 20% of patients have detectable metastases, almost always in the lungs, and this group has a lower 5-year event-free survival, generally in the 20%–30% range.
- Among patients with metastatic disease, those who achieve complete surgical removal of every tumor site after chemotherapy do much better — in the European and American Osteosarcoma Study (EURAMOS), their 5-year event-free survival reached 64% and overall survival reached 79%, compared with 28% event-free survival for the metastatic group as a whole.
- Beyond extent of disease, how strongly the tumor responds to chemotherapy, where in the skeleton it is located, and whether it can be completely removed surgically all shape the outlook.
- Among patients who are alive 5 years after diagnosis, long-term follow-up data show survival stays high but continues to decline gradually over decades, which is why monitoring matters even after the initial 5-year mark has passed.
What Is the Osteosarcoma Survival Rate?
Osteosarcoma survival rate is the term for the share of patients still living a defined length of time past diagnosis, most commonly captured as a 5-year relative survival rate. This figure benchmarks people with osteosarcoma against similarly aged and sexed members of the general population; because it is calculated from large patient cohorts, it cannot forecast any single person’s outcome.
Drawing on the most recent nationwide registry figures, the National Cancer Institute puts the 5-year relative survival odds at roughly 72% for patients under 15 at diagnosis, with a similar outlook of about 71% for those diagnosed between ages 15 and 19. Most of this progress happened decades ago: it was the shift toward pairing surgery with chemotherapy during the 1970s and 1980s that drove the gains, and outcomes have stayed fairly flat since that era.
Osteosarcoma Survival Rates by Stage and Age
Survival differs substantially depending on whether the cancer has already spread by the time it is diagnosed. Patients whose disease is localized — meaning the cancer has not spread beyond the bone where it started — tend to do considerably better than patients whose osteosarcoma is metastatic, meaning cancer cells have already reached other parts of the body. According to the National Cancer Institute, about 20% of patients already have metastases visible on imaging at diagnosis, most often in the lungs.
For patients whose osteosarcoma has metastasized at diagnosis, overall 5-year event-free survival is generally in the 20% to 30% range. In the European and American Osteosarcoma Study (EURAMOS), which enrolled patients only if their metastatic disease looked surgically removable, the group as a whole had a 5-year event-free survival of 28%; patients who went on to have every visible tumor — the primary tumor and all metastases — completely removed within 3 to 6 months of diagnosis reached a 5-year event-free survival of 64% and an overall survival of 79%. This gap shows how much surgical resectability can influence long-term outcome even within the metastatic group.
| Population / Extent of Disease | Approximate 5-Year Outcome |
|---|---|
| Children younger than 15 years (relative survival, all stages combined) | 72% |
| Adolescents 15–19 years (relative survival, all stages combined) | ~71% |
| Metastatic disease at diagnosis, group overall (event-free survival) | 28% |
| Metastatic disease with complete surgical removal of all tumor sites (event-free survival / overall survival) | 64% / 79% |
These figures describe outcomes for groups of patients studied in specific trials and registries, not a prediction for any individual case.
Factors Influencing Osteosarcoma Prognosis
Beyond overall extent of disease, several other factors shape an individual’s prognosis for osteosarcoma. Medical teams weigh all of these together, since no single factor tells the whole story.
- Primary tumor site: Among extremity tumors, those in the distal part of a limb (farther from the trunk) tend to have a better outlook than tumors closer to the trunk. Tumors in the spine or pelvis carry the greatest risk of progression, largely because complete surgical removal is harder to achieve there; National Cancer Institute data put pelvic osteosarcoma’s reported survival rates at about 20% to 47%.
- Presence of metastatic disease: As described above, this is the single most influential factor, and outcomes within the metastatic group are shaped further by how many metastases are present, whether they affect one or both lungs, and whether they can be fully removed surgically.
- Response to chemotherapy: Pathologists assess how much of the tumor has died (necrosis) after the initial round of chemotherapy given before surgery. According to the National Cancer Institute, patients whose tumors show at least 90% necrosis tend to have a better prognosis; those with less necrosis have a higher chance of relapse within the first two years. Less necrosis does not mean chemotherapy failed — cure rates in this group are still much higher than for patients who receive no chemotherapy at all.
- Surgical resectability: Removing the entire primary tumor with clean margins plays a central role in reaching a cure; when the tumor cannot be fully taken out this way, radiation therapy may be added to help keep the disease under control.
- Tumor size: Larger tumors have been linked to a worse prognosis in several patient series, whether measured by longest dimension, cross-sectional area, or estimated volume.
- Age: Patients diagnosed as older adolescents or young adults (roughly ages 18 to 40) tend to have a somewhat worse prognosis than younger patients, though age and sex appear to have a comparatively minor effect next to the factors above.
- Other markers with more limited evidence: Elevated blood levels of lactate dehydrogenase or alkaline phosphatase, and certain rarer histological subtypes, have been associated with outcome in some studies, though the evidence here is less consistent than for the factors above.
Long-Term Outlook and Follow-Up Care
Most of the risk of dying from osteosarcoma is concentrated in the first five years after diagnosis, but a smaller risk continues for decades afterward. According to the Cooperative Osteosarcoma Study Group (COSS), a German research consortium, outcomes for more than 5,500 people with osteosarcoma entered into their database from 1980 through 2019 were reviewed, singling out over 2,000 of them who had already lived at least 5 years past diagnosis to see how their outcomes unfolded from there. Overall survival among this group of longer-term survivors was 91.7% after 5 additional years of follow-up, 88.9% after 10 additional years, 85.8% after 15 additional years, and 83.4% after 20 additional years. The factors most strongly linked to a worse long-term outcome in this group were having a recurrence within the first five years, being older at the time of diagnosis, and having osteosarcoma that developed as a second cancer rather than a first one.
Many people treated for osteosarcoma go on to live full, active lives well beyond the 5-year mark. Ongoing monitoring for recurrence and for late effects of treatment, along with rehabilitation and psychosocial support, all play a role in that long-term outlook; the practical details of follow-up testing and side-effect management are covered in more depth elsewhere on this site.
Frequently Asked Questions
What is the most common age for osteosarcoma?
Osteosarcoma is diagnosed mainly in teenagers and young adults, with cases clustering around the years of the adolescent growth spurt, though younger children are sometimes affected as well. A smaller share of cases show up later in life, including tumors that develop as a second cancer years after radiation treatment for an earlier illness.
Can osteosarcoma be cured?
Osteosarcoma can be cured, particularly when it is treated with a combination of chemotherapy and surgery before the disease has spread. Outcomes have improved substantially since the 1970s, though how likely a cure is depends heavily on factors such as whether the cancer has spread at diagnosis, whether the tumor can be completely removed surgically, and how strongly it responds to chemotherapy.
What are the signs and symptoms of osteosarcoma?
Two symptoms stand out most for osteosarcoma: a swollen area over a bone and pain in that bone or a nearby joint; discomfort when lifting or putting weight on the affected arm or leg is also common. None of these are unique to cancer, so any bone or joint symptom that does not go away is worth having checked by a doctor.
Sources
